Pharmaceuticals News and Research

RSS

3SBio, DaVita partner to offer dialysis services in NE China

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD) today announced it has entered into an agreement with 3SBio Inc., a leading Chinese biotechnology developer of biopharmaceutical products, to establish a joint venture for providing dialysis treatments in northeastern China.

9 Mar 2012

Unigene fourth quarter net income increases to $4.4 million

Unigene Laboratories, Inc., today announced financial results for the fourth quarter and full-year ended December 31, 2011.

9 Mar 2012

Amylin prices public offering of 13,000,000 shares of common stock

Amylin Pharmaceuticals, Inc. today announced the pricing of an underwritten public offering of 13,000,000 shares of its common stock.

8 Mar 2012

Columbia Labs fourth quarter total net revenues decrease to $6.4M

Columbia Laboratories, Inc. today reported financial results for the three- and twelve-month periods ended December 31, 2011.

8 Mar 2012

Bellicum raises $20M in Series B financing

Bellicum Pharmaceuticals, Inc. today announced that it has raised $20 million in a Series B financing. The funding will be used to advance its lead CaspaCIDe and DeCIDe programs through Phase 2 clinical development.

8 Mar 2012

Positive phase II trial results from Circassia's ragweed allergy therapy

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that its ragweed allergy therapy has achieved positive results in a key phase II clinical trial.

8 Mar 2012

Daylight-saving time may increase risk of heart attack

Daylight-saving time this year begins March 11, and while we all might look forward to another hour of sunshine a University of Alabama at Birmingham expert says the time change is not necessarily good for your health.

8 Mar 2012

Australian TGA approves Bayer's EYLEA for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer HealthCare has received approval from the Australian Therapeutic Goods Administration (TGA) for EYLEA (aflibercept) Injection for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD) at a recommended dose of 2 milligrams (mg) via intravitreal injection per month for three consecutive months, followed by 2 milligrams via intravitreal injection every two months.

8 Mar 2012

March issue of NeuroPerspective reviews therapeutics for ADHD

NeuroPerspective, the independent, monthly review of the neurotherapeutics area, has released its March issue, which reviews the field of therapeutics for Attention Deficit Disorder.

8 Mar 2012

NMR techniques shed new light on how pharma molecules adopt different polymorphic forms

Scientists at the University of Warwick have used state-of-the-art nuclear magnetic resonance (NMR) techniques to shed new light on how pharmaceutical molecules pack together in the solid state.

8 Mar 2012

Sosei initiates SO-1105 Phase I trial in oropharyngeal candidiasis

Sosei Group Corporation, the biopharmaceutical company, today announces that its wholly owned Japanese subsidiary, Sosei Co., Ltd., has initiated a Japanese Phase I trial for SO-1105 for the treatment of oropharyngeal candidiasis.

8 Mar 2012

Lilly, Boehringer Ingelheim announce availability of Jentadueto tablets

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced Jentadueto (linagliptin/metformin hydrochloride) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S.

8 Mar 2012

Zalicus fourth quarter revenue decreases to $8.2 million

Zalicus Inc. today reported financial results for the fourth quarter and year ended December 31, 2011.

8 Mar 2012

Researchers validate CatB protease as target for Alzheimer's

Researchers at the University of California, San Diego, the Medical University of South Carolina, the University of Cincinnati, and American Life Science Pharmaceuticals of San Diego have validated the protease cathepsin B (CatB) as a target for improving memory deficits and reducing the pathology of Alzheimer's disease (AD) in an animal model representative of most AD patients.

8 Mar 2012

BioLineRx receives European patent for BL-1020 to treat schizophrenia

BioLineRx, a biopharmaceutical development company, announced today that a European patent has been granted claiming BL-1020's composition and its use for the treatment of schizophrenia.

8 Mar 2012

Fera introduces Sulfacetamide Ointment for conjunctivitis

Fera Pharmaceuticals is pleased to announce the launch of Sulfacetamide Sodium Ophthalmic Ointment USP, 10%.

7 Mar 2012

Autism Research Institute Conference to take place in Newark, N.J.

The Autism Research Institute, a pioneer organization in the biomedical, whole-body approach to autism, will host leading experts at the Autism Research Institute (ARI) Conference from Thursday, April 26 through Sunday, April 29 at the Newark Airport Marriott in Newark, N.J.

7 Mar 2012

A&G, Mayo Medical sign license agreement for new progranulin blood test for FTD

Mayo Clinic today announced that Mayo Medical Laboratories has signed an agreement with A&G Pharmaceutical, Inc. and will receive a non-exclusive license to certain patent rights and proprietary antibody reagents for the detection and measurement of progranulin in blood.

7 Mar 2012

Shire to commence two Vyvanse and Concerta Phase 4 comparison trials for ADHD

As part of its continued commitment to ADHD research, Shire plc, the global specialty biopharmaceutical company, today announced it is initiating two Phase 4 clinical trials to compare Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) to Concerta (methylphenidate HCl) Extended-Release Tablets.

7 Mar 2012

FDA issues Complete Response Letter to Eisai for Dacogen sNDA

Astex Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has issued a Complete Response Letter to partner Eisai for their supplemental New Drug Application (sNDA) for Dacogen (decitabine) for Injection for patients with acute myeloid leukemia (AML) in adults 65 years of age or older who are not considered candidates for induction therapy.

7 Mar 2012